ArticleCurrent oncology (Toronto, Ont.)2024

Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis.

Dahlia Sano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.